Status:
COMPLETED
Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
Enzon Pharmaceuticals, Inc.
Conditions:
Acute Lymphoblastic Leukemia
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
The goal of this clinical research study is to learn if a special combination of chemotherapy drugs called "augmented hyper-CVAD chemotherapy" given over 6 to 8 months followed by monthly maintenance ...
Detailed Description
The augmented hyper-CVAD chemotherapy is a combination of chemotherapy drugs including cyclophosphamide, vincristine, adriamycin, dexamethasone, and pegaspargase given together for one "course" of tre...
Eligibility Criteria
Inclusion
- Previously treated acute lymphoblastic leukemia (ALL) (including Burkitt's lymphoma) or lymphoblastic lymphoma in relapse or primary refractory;
- No age restrictions;
- Zubrod performance status \</= 3;
- Adequate liver (bilirubin \</= 3mg/dl unless considered due to tumor) and renal function (creatinine \</= 3mg/dl unless considered due to tumor);
- Adequate cardiac function (New York Heart Association (NYHA) \< III as assessed by history and physical examination)
Exclusion
- Not Applicable
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00890656
Start Date
June 1 2003
End Date
January 1 2011
Last Update
February 20 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030